La Jolla Pharmaceutical Announces FDA Approval of Giapreza

On December 21, La Jolla Pharmaceutical Company (LJPC) announced that the FDA approved its drug, Giapreza (angiotensin II). The drug can be used to increase blood pressure in adult patients suffering from septic shock or other distributive shock. La Jolla expects to have the drug available for patients in March 2018.

Rocket Tickers detected the event and alerted subscribers at 6:15 pm. The next trade took place for $32.45 at 6:19 pm. Regular market trading opened the following morning at $30.97. The stock price pushed higher throughout the day before closing at $31.45. La Jolla’s stock continued to trend higher on the news for the next five trading sessions. The stock closed at $33.79 on January 2, which was a gain of over 9% for investors from the market open on December 22.

Visit the Knowledge Center for more information about clinical trials and how to trade them.

Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.

Subscribe here if you would like to start receiving these signals in real-time and start trading!

SaveSave